Monoamine Oxidase B Antibody - BSA Free

Immunohistochemistry-Paraffin: Monoamine Oxidase B Antibody [NBP1-87493]

Immunohistochemistry-Paraffin: Monoamine Oxidase B Antibody [NBP1-87493] - Staining of human duodenum shows strong granular cytoplasmic positivity in glandular cells.

Immunohistochemistry-Paraffin: Monoamine Oxidase B Antibody [NBP1-87493]

Immunohistochemistry-Paraffin: Monoamine Oxidase B Antibody [NBP1-87493] - Staining of human liver shows moderate to strong granular cytoplasmic positivity in hepatocytes.

Immunohistochemistry-Paraffin: Monoamine Oxidase B Antibody [NBP1-87493]

Immunohistochemistry-Paraffin: Monoamine Oxidase B Antibody [NBP1-87493] - Staining of human testis shows moderate to strong granular cytoplasmic positivity in Leydig cells.

Western Blot: Monoamine Oxidase B Antibody - BSA Free [NBP1-87493] -

Glutamate-driven astrocytic MAO-B leading to reactive astrogliosis and astrocytic scar formation. a Schematic representation of glutamate-driven astrocytic MAO-B inducing reactive astrogliosis and astrocytic scar formation. b-d Western blot analysis for EAAT1 and MAO-B expression in astrocyte monocultures upon glutamate treatment. Glutamate treatment increased MAO-B expression in astrocytes. Blockage of glutamate transport activity by using glutamate transporter inhibitor (TBOA) decreased MAO-B expression. e, f Reactivity of astrocyte monocultures upon glutamate treatment assessed by immunostaining with GFAP. Inhibiting glutamate transport (TBOA) or MAO-B (KDS2010) decreased GFAP expression. g ELISA for CSPGs deposited from reactive astrocytes. h, i Immunofluorescence images and quantification of GFAP intensity in the mouse tissues. j, k Immunofluorescence images and quantification of CSPGs intensity in the mouse tissues. Quantitative data were presented as means +/- SD (n = 3, unless otherwise noted). *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. p values were calculated by two-tailed unpaired Student's t-test for comparisons between two groups, and by one-way ANOVA for multiple comparisons. Scale bars represent 100 μm Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37468961), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Flow Cytometry: Monoamine Oxidase B Antibody - BSA Free [NBP1-87493] -

MAO-B-positive mitovesicles are more numerous in the brain than MAO-A-positive mitovesicles. (A, B) Representative flow cytometry analyses of Fr8 brain EVs (mitovesicle-enriched, second columns) immunolabeled with antibodies against MAO-A (A) and MAO-B (B). The left columns show the same analyses performed on a 1:1:1 v/v mixture of Fr1, Fr2, and Fr3 EVs (microvesicle-enriched) isolated from the same brains (negative control). The right columns show mitovesicles incubated with the secondary antibody only. The gating strategy is shown for all conditions (first rows). Both the y- and the x-axis are in a log10 scale. 20,000 EVs were acquired for each experiment. FSC-A: forward scatter– area. SSC-A: side scatter– area. Ab: antibody. (C) Percentage of mitovesicles positive for either MAO-A or MAO-B. n = 3 mice per group. The percentage of positive EVs was determined on the basis of the secondary antibody control gate of each sample (set to 0.8% maximum). Bars: mean +/- SEM. Statistical test used: two-tailed, unpaired Student’s t-test. MAO-A vs. MAO-B, P = 0.0004. *** P < 0.001 Image collected and cropped by CiteAb from the following open publication (https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s…), licensed under a CC-BY license. Not internally tested by Novus Biologicals.